依洛尤单抗对冠状动脉斑块成分的影响:GLAGOV研究射频分析
GLAGOV研究纳入968例他汀治疗的冠心病患者,随机接受安慰剂或依洛尤单抗420mg每月一次治疗76周,其中331例可评估射频超声斑块成分。与单用他汀相比,依洛尤单抗进一步降低LDL-C并促进斑块总体积消退,但斑块成分(钙化、纤维、纤维脂肪、坏死核心)变化无差异。
要点
- 依洛尤单抗加他汀较单用他汀进一步降低LDL-C并减小斑块负荷。
- 两组间斑块成分(钙化、纤维、纤维脂肪、坏死)变化无显著差异。
- LDL-C变化与斑块钙化呈弱负相关(r=-0.15,p<0.001)。
核心结论
- 在他汀治疗基础上加用依洛尤单抗未产生与单用他汀不同的斑块成分变化。
- 虚拟组织学成像对依洛尤单抗斑块效应的评估可能不提供超越斑块负荷测量的额外信息。
研究设计与样本
- GLAGOV研究为随机对照试验,968例他汀治疗的冠心病患者接受系列冠状动脉血管内超声成像。
- 患者随机接受安慰剂或依洛尤单抗420 mg每月一次治疗76周。
- 331例患者有可评估的超声背散射信号射频分析用于斑块成分测定。
主要发现
- 依洛尤单抗组LDL-C降至33.5 mg/dl,安慰剂组为89.9 mg/dl(p < 0.0001)。
- 依洛尤单抗组斑块百分比体积变化为-1.2%,安慰剂组为+0.17%(p < 0.0001)。
- 依洛尤单抗组斑块总体积变化为-3.6 mm3,安慰剂组为-0.8 mm3(p = 0.04)。
- 两组间钙化(1.0 ± 0.3 mm3 vs. 0.6 ± 0.3 mm3;p = 0.49)、纤维(-3.0 ± 0.6 mm3 vs. -2.4 ± 0.6 mm3;p = 0.49)、纤维脂肪(-5.0 ± 1.0 mm3 vs. -3.0 ± 1.0 mm3;p = 0.49)和坏死(-0.6 ± 0.5 mm3 vs. -0.1 ± 0.5 mm3;p = 0.49)体积变化无差异。
- LDL-C变化与斑块钙化呈负相关(r = -0.15;p < 0.001)。
临床怎么用
- 对于他汀治疗的冠心病患者,加用依洛尤单抗可进一步降低LDL-C并促进斑块负荷消退。
- 虚拟组织学成像评估斑块成分变化可能不提供依洛尤单抗疗效的额外信息,斑块负荷测量仍是主要评估手段。
局限性
- 斑块成分分析仅基于331例有可评估射频信号的患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Incremental low-density lipoprotein (LDL) cholesterol lowering with the proprotein convertase subtilisin kexin type 9 inhibitor evolocumab regresses coronary atherosclerosis in statin-treated patients. OBJECTIVES: The purpose of this study was to evaluate the effect of adding evolocumab to statin therapy on coronary plaque composition. METHODS: A total of 968 statin-treated coronary artery disease patients underwent serial coronary intravascular ultrasound imaging at baseline and following 76 weeks of treatment with placebo or evolocumab 420 mg monthly. Plaque composition changes were determined in 331 patients with evaluable radiofrequency analysis of the ultrasound backscatter signal. RESULTS: Compared with statin monotherapy, evolocumab further reduced LDL cholesterol (33.5 mg/dl vs. 89.9 mg/dl; p < 0.0001) and induced regression of percent atheroma volume (-1.2% vs. +0.17%; p < 0.0001) and total atheroma volume (-3.6 mm3 vs. -0.8 mm3; p = 0.04). No difference was observed between the evolocumab and placebo groups in changes in calcium (1.0 ± 0.3 mm3 vs. 0.6 ± 0.3 mm3; p = 0.49), fibrous (-3.0 ± 0.6 mm3 vs. -2.4 ± 0.6 mm3; p = 0.49), fibrofatty (-5.0 ± 1.0 mm3 vs. -3.0 ± 1.0 mm3; p = 0.49), and necrotic (-0.6 ± 0.5 mm3 vs. -0.1 ± 0.5 mm3; p = 0.49) volumes. An inverse correlation was observed between changes in LDL cholesterol and plaque calcification (r = -0.15; p < 0.001). CONCLUSIONS: The addition of evolocumab to a statin did not produce differential changes in plaque composition compared with statin monotherapy. This suggests that evaluation of plaque morphology using virtual histology imaging may provide no incremental information about the plaque effects of evolocumab beyond measurement of plaque burden. (GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound [GLAGOV]; NCT01813422).
引用
- Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol. 2018. PMID: 30336824. doi:10.1016/j.jacc.2018.06.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。